読み込み中
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
前日終値
$88.15
−$0.90 · -1.01%
日中の時刻はETです。市場データは遅延する場合があります。
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
日中レンジ
現在 $88.15
52週レンジ
現在 $88.15
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
31
割高
センチメント
55
まちまち
リスク
35
中程度のリスク
モメンタム
65
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
日中レンジ
現在 $88.15
52週レンジ
現在 $88.15
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$156
上昇余地（76.97%）この株式へのエクスポージャーを報告している上場投資信託です。
iShares Biotechnology ETFIBB5015.22万0.48%102.79億 USD0.44%$206.49+3.00%
Schwab International Equity ETFSCHF1624.06万0.02%670.06億 USD0.03%$27.27+0.66%
Goldman Sachs Hedge Industry VIP ETFGVIP922.66万1.59%5.79億 USD0.45%$172.85+0.79%
State Street SPDR Portfolio Developed World ex-US ETFSPDW530.86万0.01%404.62億 USD0.03%$49.98+0.64%
Vanguard Total International Stock ETFVXUS316.37万0.00%6657億 USD0.05%$84.82+0.86%
Militia Long/Short Equity ETFORR289万0.83%3.46億 USD10.91%$38.52+1.02%
Vanguard FTSE Developed Markets ETFVEA210.48万0.00%3238億 USD0.03%$70.35+0.70%
Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSM166.69万0.24%6.89億 USD0.89%$57.70+0.92%iShares Biotechnology ETFIBBSchwab International Equity ETFSCHFGoldman Sachs Hedge Industry VIP ETFGVIPState Street SPDR Portfolio Developed World ex-US ETFSPDWVanguard Total International Stock ETFVXUSMilitia Long/Short Equity ETFORRVanguard FTSE Developed Markets ETFVEAMorgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
